AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, issues at a Novo plant are ...
A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema ...
CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback